Francis D, 451
Fraser VJ, 350
Frutos B, 130
Fuchs D, 441
Fukuda Y, 547

Gallaher W, 373
Galvão-Castro B, 426
Gao Z, 80
Garber GE, 124
García F, 55
Garland M, 433
Gatell JM, 55
Gattinara GC, 230
Gendre J-P, 34
Georges-Courbot MC, 430
Gérard L, 50
Gershon A, 451
Gialeraki A, 89
Giri A, 542
Goldfarb J, 462
Goldstein H, 145
Goodenow MM, 99
Gourevitch MN, 361
Govindarajan S, 40
Greenblatt RM, 513
Greisberger C, 135
Griffioen A, 546
Groupe d'Epidémiologie Clinique du Sida en Aquitaine, 198
Guerrero A, 130
Guillin V, 178
Gwinn M, 158, 506

Halbert J, 274
HAM/TSP Brazilian Study Group, 536
Hamers FF, 296
Hammache D, 221
Hammill H, 462
Hardy WD Jr, 513
Harrison LH, 403
Hatiashvili D, 1
Hatzakis A, 89
Hawkins E, 451
Hawley-Foss N, 124
Hayakawa T, 547
Hayman CR, 67
Hendel H, 381
Henderson RA, 150
Hénon N, 381
Henry K, 339
Hershow R, 513
Hess G, 408
Heyward WL, 289
Hillyer CD, 210
Hirsch MS, 339
Hisada M, 421
HIV Outpatient Study (HOPS) Investigators, 182
Hodes D, 462
Hofer C, 403
Hogg RS, 61
Holden-Wiltse J, 135
Holmberg SD, 182
Holtgrave DR, 282
Houston S, 124
Hoxie N, 282
Hunsmann G, 441
Hutton N, 150

Iskandriati D, 542
Israel H, 519
Izopet J, 478

Janssen RS, 67
Jeffe DB, 350
Jenson H, 462
Johnson D, 451
Johnson JL, 484
Joloba M, 484
Jones D, 441
Joubert G, 238
Jugsudee A, 165
June CH, 210
Jurkiewicz E, 441

Kahn JO, 339
Kalish LA, 513
Kamya MR, 484
Kang M, 451
Kapsimali V, 89
Karafoulidou A, 89
Karon JM, 67, 158
Kasasa S, 484
Kashima S, 74
Katsarou O, 89
Katz MH, 178
Katz SL, 451
Katzman M, 99
Keefer MC, 519
Keet IPM, 254
Kellogg T, 178
Kemper CA, 367
Kenefic L, 381
Kent G, 367
Kenton A, 339
Kerndt PR, 413
Keruly JC, 29
Khorasheh S, 498
Kim A, 145
Kim LS, 44
Kinson Z, 546
Kitayaporn D, 289
Kitsiripornchai S, 165
Klein RS, 361
Kmack A, 339
Koch J, 44
Kotranski L, 274
Kotze M, 238
Kovacs A, 462
Kravcik S, 124
Krol A, 254

Labarca J, 471
Lachgar A, 381
Lago TDG, 189
Lalezari J, 195
Lambert JS, 451
Lamers SL, 99
Landay A, 408
LaRussa P, 462
Lauby J, 274
Leal M, 55
Lebuanec H, 381
Lederman MM, 408
Lee CA, 546
Lee C-M, 393
Leedom J, 135
Leigh JE, 373
Lemp GF, 178
Leone F, 490
Leport C, 50
Levin M, 451
Levine A, 513
Lieberman J, 111
Likanonsakul S, 315
Lima LAA, 403
Lin R-Y, 393
Liou S-H, 339
Liu H, 80
Livadiotti S, 230
Livingston R, 451
Lo JC, 307
Longshore D, 200
Louisirirotchanakul S, 315
Lu S, 413
Lu W, 381
Lu X, 6
Lu Y, 6
Lucotte G, 174
Lüke W, 441
Luo W, 373

Ma Z, 80
Maas JJ, 254
Machado AA, 74
MacKellar D, 178
MacKellar DA, 67
Makuwa M, 430
Mallolas J, 55
Man MC, 203
Mandalaki T, 89
Marchou B, 478
Marfil S, 19
Markowitz LE, 165
Martial J, 308
Martí-Belda P, 130
Martin MP, 430
Martin N, 451
Martindale SL, 61
Martinez A, 339
Martínez-Picado J, 19
Maslo C, 34, 50
Mason CJ, 165
Massip P, 478

Mastro TD, 289, 315
Mauch MY, 245
Mayne A, 210
McElrath MJ, 519
McFarland J, 387
McFarland W, 178
McIntosh K, 462
McNamara J, 451
McSherry G, 451
Meehan PM, 135
Méndez C, 471
Menna-Barreto M, 536
Menu E, 308
Mercier G, 174
Meredith KL, 350
Michael NL, 430
Michael RA, 165
Miller CJ, 6
Milona I, 89
Miró JM, 55
Montaner JSG, 61
Montefiori DC, 6
Moore RD, 29
Moorman AC, 182
Morace G, 490
Moreno R, 548
Morlat P, 198
Morse G, 135
Moulton LH, 403
Moye J Jr, 451
Muchinik G, 548
Mueller N, 421
Mugerwa RD, 484
Muller-Trutwin MC, 308
Mulligan K, 307
Mundy LM, 350
Munsiff SS, 361
Myers MM, 433
Mylonakis E, 306

Nabias R, 430
Nakashima AK, 266
National Institutes of Health–sponsored Pediatric AIDS Clinical Trials Group (ACTG-218), 451
Neisson-Vernant C, 308
Nevin T, 135
Newell M-L, 189
Niβlein T, 441
Nijhuis M, 19
Nitayaphan S, 165
NV15107 Study Group, 195

O'Brien S, 381
O'Brien SJ, 430
Odem S, 413
Okayama A, 421
Orlandi P, 230
Ortona L, 490
O'Shaughnessy MV, 61
Ouka M, 308

Padian NS, 527
Palella FJ, 182
Pamungkas J, 542
Para M, 135
Pasquier C, 478
Patarca R, 121
Pauza CD, 6
Peavy H, 462
Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection ($P^2C^2$ HIV) Study Group, 462
Pegues CF, 413
Pellegrin JL, 198
Perez MD, 130
Perez-Elías MJ, 130
Petry H, 441
Pettoello-Mantovani M, 145
Phair J, 339
Pieters H, 238
Pinkerton SD, 282
Pinto ME, 310
Pitt J, 462
Poncelet H, 381
Powderly W, 135
Puel J, 478
Puig T, 19
Pumarola T, 55
Purcell DW, 266

Qian D, 40

Rabbi MF, 321
Rached AA, 34
Ragnaud JM, 198
Raktham S, 289
Rappaport J, 381
Reichman RC, 135
Reiser WJ, 282
Renaut A, 430
Resenhoeft R, 282
Resnick L, 135
Rich J, 306
Richard V, 198
Richards AL, 542
Riley JL, 210
Rodrigues LC, 189
Roebuck KA, 321
Romiti ML, 230
Roos MThL, 254
Rosen DH, 158
Rosen L, 542
Rosenberg F, 1
Røsok BI, 332
Rossi P, 230
Rozenbaum W, 34
Rubinstein ML, 260
Ruiz L, 19, 55

Sabin CA, 546
Sackoff J, 387
Saito H, 547
Salama G, 478
Samudio M, 548
Sanders JC, 99
Sandres K, 478
Santoro-Lopes G, 403
São Paulo Collaborative Study for Vertical Transmission of HIV-1, 189
Satten GA, 506
Scaccia S, 230
Schächter F, 381
Schambelan M, 307
Schechter M, 310, 403
Schechter MT, 61
Schiffman FJ, 306
Schluchter M, 462
Selwyn PA, 260
Semaan S, 274
Shaffer N, 315
Shankar P, 111
Shaw M, 178
Shea T, 197
Shearer W, 462
Sheon AR, 519
Sheppard HW, 430
Shiboski SC, 527
Shima T, 421
Sie A, 542
Sikic BI, 203
Singer J, 498
Sirisopana N, 165
Skinner LM, 99
Smith G, 451
Smith MW, 381
Sobesky G, 308
Song S, 321
Song W, 80
Sorvillo F, 413
Soza X, 471
Sperling R, 462
Sprang H, 111
Spurkland A, 332
Ssali FN, 484
Stahl-Hennig C, 441
Stansell J, 44
Stark RI, 433
STD Clinic HIV Seroincidence Study Group, 506
Steele C, 373
Steger KA, 245
Steinberg S, 158
Steyn M, 238
Stone VE, 245
Strathdee SA, 61
Stuver S, 421
Su S, 387
Suarez M, 130
Sujarita S, 289
Sullivan PS, 266
Supapongse T, 165
Supplement to HIV/AIDS Surveillance Study Group, 266
Sutherland D, 124
Sweeney J, 306

Sweeney S, 506
Szeto HH, 433

Tacconelli E, 490
Tai VW, 307
Takamatsu J, 547
Talesnik E, 471
Talusan K, 150
Tamalet C, 221
Tanuri A, 310
Tartakovsky B, 1
Telzak EE, 513
Tess BH, 189
Tierney C, 339
Timpone J Jr, 135
Tortajada C, 55
Torugsa K, 165
Touloumi G, 89
Tourrès C, 221
Toyoda H, 547
Trimoulet P, 198
Tropper PJ, 433
Tsubouchi H, 421
Tumbarello M, 490
Tuomala R, 462
Turner D, 1

Valdez H, 408
Valinluck B, 40
Valleroy LA, 67, 178
van Ameijden EJC, 254
van der Ryst E, 238
van der Westhuizen M, 238
van Leeuwen R, 254
van Staden M, 238
VanCott TC, 165, 451
Vanichseni S, 289
Vaniyapongs T, 289
Vardinon N, 1
Venter C, 238
Vera ME, 548
Vergeront J, 282
Vial PA, 471
Victor G, 124
Vidal C, 55
Villinger F, 210
Von Bargen JC, 182

Wabwire-Mangen F, 484
Wachter H, 441
Wagner L, 519
Walker C, 408
Walmsley SL, 498
Wara D, 451
Ward JW, 266
Washington CB, 203
Wasi C, 289, 315
Wathen LK, 135
Weber J, 315
Wegner SA, 430
Weinstock H, 506
Williams D, 484
Winkler CA, 381
Wohl AR, 413
Women's Interagency HIV Study, 513
Wood K, 135
Woolley I, 408
Wormley FL Jr, 373
Wortley PM, 158

Xie J, 80

Yahi N, 221
Yogev R, 451
Yolken RH, 150
Young NL, 289
Yu W, 80
Yust I, 1

Zagury D, 381
Zagury J-F, 381
Zapiola I, 548
Zdunek D, 408
Zimmerman E, 519
Zuckerman E, 513

*Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*
**19**:556–562 © 1998 Lippincott Williams & Wilkins, Philadelphia

# Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 19, 1998

## Subject Index

Acquired immunodeficiency syndrome (AIDS)
  progression to
    *CCR5*, *CCR2*, and SDF1 genetic polymorphisms in, 381
    in hemophilia cohort, 89
  protease inhibitors for cytomegalovirus retinitis of, 130
Adolescents, HIV infection among, 67
Advanced AIDS, reverse transcriptase inhibitor therapies in treatment of, 339
Africa
  community-acquired bloodstream infections among febrile adults in, 484
  HIV-2 and HTLV-I/II in semiurban population of (letter), 430
  total lymphocyte count, CD4+ count, and CD4+ percentage in HIV-1-infected patients of, 238
African-Americans
  HIV infection among, 67
  women, sociodemographic and behavioral characteristics of, 413
Age, in HIV progression in hemophilia cohort, 89
Anemia
  combination antiretroviral therapy with protease inhibitors with (letter), 306
  HIV survival and, 29
Animal models
  antiviral antibody response to pathogenic SHIV in, 6
  for autotransfusion therapy, 210
  of zidovudine kinetics during pregnancy, 433
Antibody binding/neutralization, in characterizing HIV-1 subtypes B and E sera, 315
Antibody response, to tetanus toxoid and pneumococcal capsular polysaccharides, 471
Anti-CD3/CD28 expanded cells, in vitro characterization of, 210
Anti-HIV protease inhibitors, interaction with P-glycoprotein in human cultured cells, 203
Antiretroviral therapy
  factors in recognition and use of, 350
  HIV-1 DNA decay in, 478
  in HIV-infected chronic anemia patients (letter), 306
  improved outcome of cytomegalovirus retinitis with, 130
  in perceived risk of HIV transmission and need for safe sex, 124
  survival benefits of, 339
Antiretroviral-naive patients, peak viral load drop in response to nucleoside reverse transcriptase inhibitors in, 55
A2-restricted reverse-transcriptase epitope, cytotoxic T-lymphocyte clones directed against, 111
Asia
  HIV-1 subtypes B and E in injection drug users of, 289
  molecular epidemiology and trends of HIV-1 subtypes in, 393
  surveillance of HIV-1 prevalence and subtype in young men of, 165
Atevirdine mesylate monotherapy, phase I study of, 135
Attitudes
  antiretroviral therapy and viral load effect on, 124
  toward women and minorities in AIDS clinical trials, 245
Autotransfusion therapy, developing animal model for, 210

Bacteremia, in febrile adults, 484
Behavioral characteristics, of African-American women with HIV and AIDS, 413
Bioavailability, of anti-HIV protease inhibitors, 203
Bisexual men, determinants of sexual risk-taking among, 61
Bloodstream infections
  community-acquired in febrile adults, 484
  nosocomial in HIV-infected patients, 490
Body composition, in children with HIV, 150
Body mass index course, in asymptomatic HIV-1 in homosexual men, 254
Body shape, changes in HIV-infected patients (letter), 307
Brazil
  discontinuous introduction of HIV subtypes B and F into (letter), 310
  gender and survival after AIDS in, 403
  HIV-1 V3 loop variants in, 74
  HTLV-I-associated myelopathy/tropical spastic paraparesis in, 536
  infant feeding and risk of mother-to-child transmission in, 189
Breast-feeding, risk of vertical transmission through, 189

Candidiasis, oropharyngeal, Th1/Th2 cytokines in, 373
*CCR5*
  in AIDS progression, 381
  32-bp deletion, distribution of in Europe, 174
  mutant, decreased susceptibility of PBMCs in heterozygotes for, 145
*CCR2*, in AIDS progression, 381
CD25, cell surface expression of, 332

CD4(+) cell count
in AIDS survival analysis, 403
correlation with total lymphocyte count and CD4+ percentage, 238
with reverse transcriptase inhibitors, 339
CD8+ cell count, in AIDS survival analysis, 403
CD4(+) lymphocytes
body mass index and in asymptomatic HIV-1-infected gay men, 254
inhibition of SIV replication in, 210
lysis by cytotoxic T-lymphocyte clones, 111
CD8+ T cells, activation and proliferation of in lymphoid tissues of HIV-1-infected individuals, 332
Cell-mediated immunity, altered, in asymptomatic patients with positive or indeterminate HTLV-I serology, 121
Cellular proliferation, in lymphoid tissue, 332
Chemokines, in advanced HIV disease, 1
Chemoprophylaxis failure, in ambulatory HIV-infected patients, 182
Childbearing women, HIV prevalence trends among, 158
Children
HIV-infected, resting energy expenditure and body composition in, 150
safety and immunogenicity of HIV recombinant envelope vaccines in, 451
zidovudine-related HIV-1 reverse transcriptase gene mutations in, 230
Chinese, sexual behavior among, 80
Clinical trials
discrimination against volunteers in, 519
provider attitudes toward women and minorities participating in, 245
Coinfection
of hepatitis C virus and HTLV-I, 421
with hepatitis G virus and HIV disease progression in hemophilic (letter), 546, 547
Colombia, altered cell-mediated immunity in asymptomatic patient with positive or indeterminate HTLV-I serology in, 121
Combination therapy
efficacy of in HIV-1 infection, 19
in HIV-infected chronic anemia patients (letter), 306
Community-acquired bloodstream infections, in febrile adults, 484
Controlled clinical trials, discrimination against volunteers in, 519
Cotton-wool spots, in primary HIV infection (letter), 197
Counseling services, HIV seropositivity rates in, 282
Crack use
in African-American women with HIV and AIDS, 413
temporal trends in HIV risk behaviors with, 274
Crossover treatment trial, for HIV-infected patients with peripheral neuropathy, 367
Cryptosporidiosis, sex- and water-associated risk behaviors for, 44
*CXCR4* polymorphisms, HIV-1 pathogenesis and (letter), 430
Cytokines
in HIV-1 transcription activation in latently infected T cells, 321
intracellular levels and HIV progression, 1
in saliva, 373
Cytomegalovirus infection
in HIV progression in hemophilia cohort, 89
in mother-infant transmission, 462
Cytomegalovirus retinitis, improved outcome of after protease inhibitor introduction, 130
Cytotoxic T lymphocytes, directed against A2-restricted reverse-transcriptase epitope, 111

Δ32 allele, of *CCR5* gene, 174
Diarrhea, weight loss and, 34
Didanosine, survival benefits of, 339
Discrimination, against volunteers in prophylactic HIV vaccine trials, 519
Disease progression
body mass index and in asymptomatic HIV-1-infected gay men, 254
*CCR5, CCR2,* and SDF1 genetic polymorphisms in, 381
in HBeAg-positive patients (letter), 198
in hemophilia cohort, 89
immune reactivity to gp41 and, 441
tuberculosis in, 361
Drug resistance, in phase I study of atevirdine mesylate monotherapy, 135
Drug use
in African-American women with HIV and AIDS, 413
geographical differences in among HIV-seropositive gay men, 266
HIV-1 subtypes B and E and, 289

East Gabon, HIV-2 and HTLV-I/II in semiurban population of (letter), 430
Ebstein-Barr virus, in mother-infant transmission, 462
Energy metabolism, in HIV-infected children, 150
Epidemiology
of hepatitis G virus, 40
of HIV among childbearing women, 158
of HIV-1 in young Thai men, 165
of HIV infection in infants, 189
of HIV infectivity, 527
of HIV-1 subtypes B and E in injection drug users, 289
of HIV-1 subtypes in Taiwan, 393
of HTLV-I-associated myelopathy and tropical spastic paraparesis, 536
in injection drug users and crack smokers, 274
Erratum: Infant Feeding and Risk of Mother-to-Child Transmission of HIV-1 in Sao Paulo State, Brazil (1998; 19:189-94), 550
Erythropoietin, survival in HIV infection and, 29
Ethnicity, HIV prevalence and, 67
Europe
distribution of *CCR5* gene 32-bp deletion in, 174
HIV prevalence in pregnant women in, 296

Fetus, zidovudine kinetics and, 433
Fever, community-acquired bloodstream infections with, 484
French West Indies, HIV-1 subtype A introduction in (letter), 308

Gangliosides, HIV-1-induced perturbations of, 221
Gay men
  body mass index course in asymptomatic HIV-1-infected, 254
  determinants of sexual risk-taking among, 61
  geographical differences in substance use by, 266
  high prevalence of HIV and risk behaviors among, 178
  preventing discrimination against, 519
Gender
  in HTLV-I infection in injection drug users, 426
  and participation in AIDS clinical trials, 245
  survival and, 403
Genetic polymorphisms, effects of in AIDS progression, 381
Genetic variability, in Brazil, 74
Genotype resistance, efficacy of indinavir in, 19
Geographic differences, in substance use among HIV-seropositive gay men, 266
Glutathione, deficiency of in hypersensitivity reactions, 498
Glycolipids, HIV-1-induced perturbations of, 221
Glycosphingolipid metabolism, HIV-1-induced perturbations of, 221
gp41, immune reactivity to in protection from SIV infection, 441
gp130 oligomers, immunization with in Rhesus monkeys, 441
Greece, determinants of HIV infection progression in hemophilia cohort in, 89
Growth, in HIV-infected children, 150
GWG amino acid sequence, in HIV-1 variant, 74

HBeAg-positive patients, rapid HIV progression in (letter), 198
Hemophilia
  hepatitis G virus and HIV disease progression in (letter), 546, 547
  HIV progression in, 89
Hepatitis B virus, in HIV-infected patient sera, 40
Hepatitis C virus
  in HIV-infected patient sera, 40
  in purified protein derivative skin reactivity suppression, 421
Hepatitis G virus
  in HIV disease progression in hemophilic (letter), 546, 547
  RNA
    in AIDS patient plasma, 408
    in HIV-infected patient sera, 40
Heteroduplex mobility assay, for HIV-1 subtypes, 393
Heterosexual transmission, time variation in HIV infectivity and, 527
High-risk population, HTLV-I/II seroprevalence among, 513
HIV-1 integrase sequences, analysis of, 99
HIV medications, factors in recognition and use of, 350
HIV recombinant envelope vaccines, safety and immunogenicity of in HIV-infected infants and children, 451
HIV-1 reverse transcriptase gene mutations, zidovudine-related, 230
HIV risk behavior, in injection drug users and crack smokers, 274
Homosexuality
  HIV seroincidence and, 506
  male, preventing discrimination against, 519
HTLV-I-associated myelopathy/tropical spastic paraparesis, in Brazil, 536
HTLV-I/II
  altered cell-mediated immunity in, 121
  antibodies, among Indian groups from Paraguay (letter), 548
  carriers of, hepatitis C virus in, 421
  in male and female injection drug users of northeast Brazil, 426
  in semiurban African population (letter), 430
  seroprevalence of among HIV-infected women and women at risk for HIV, 513
Human immunodeficiency virus (HIV) antibody, in vaccine trial volunteers, 519
Human immunodeficiency virus (HIV) infection
  anemia and survival in, 29
  antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in, 471
  in disadvantages out-of-school youth, 67
  disease progression of
    determinants of in hemophilia cohort, 89
    hepatitis G virus and (letter), 546, 547
    rapid, in HBeAg-positive patients (letter), 198
  hepatitis G virus and, 40
  increased intracellular macrophage inflammatory protein-1á in advanced stages of, 1
  insomnia in, 260
  prevalence of
    among childbearing women in U.S., 158
    among disadvantaged out-of-school youth, 67
    among injection drug users (letter), 200
    among young homosexual men, 178
    in young Thai men, 165
  resistance to in *CCR5* gene deletion homozygous individuals, 145
  seroincidence of in STD clinic patients, 506
  seropositivity of in outreach-based counseling and testing services, 282
  seroprevalence of among disadvantaged out-of-school youth, 67
  sex- and water-associated risk behaviors for cryptosporidiosis in, 44
  subtypes B and F, discontinuous introduction of (letter), 310
  total lymphocyte count, CD4+ count, and CD4+ percentage in, 238
  transmission of, antiretroviral therapy and viral load effect on perceived risk of, 124
Human immunodeficiency virus (HIV) testing
  services for, HIV seropositivity rates in, 282
  in vaccine trial volunteers, 519
Human immunodeficiency virus type 1 (HIV-1)
  advanced, efficacy of indinavir with reverse transcriptase nucleoside analogues, 19
  antibody of in sera from subjects with HIV-1 subtypes B and E, 315
  DNA decay in suppressive antiretroviral therapy, 478
  genetic sequences for epidemiology and trends of subtypes of, 393
  latent, 478
  maternal and perinatal factors in mother-infant transmission of, 462

pathogenesis of
CXCR4 polymorphisms and (letter), 430
glycosphingolipid metabolism disturbances in, 221
phase I study of atevirdine mesylate monotherapy for, 135
RNA
body mass index and, 254
with reverse transcriptase inhibitors therapies, 339
subtype A, in French West Indies (letter), 308
subtypes B and E
characterization of sera from subjects with, 315
in injection drug users, 289
subtypes of, molecular epidemiology and trends of, 393
transcription of in latently infected T cells, 321
V3 loop variants, in Brazil, 74
Human immunodeficiency virus type 2 (HIV-2), in semiurban African population (letter), 430
Hypersensitivity reactions, to trimethoprim-sulfamethoxazole, 498

Immunotherapy, safety and immunogenicity of in children and infants, 451
Incidence
of HIV among childbearing women, 158
of HIV in STD clinic patients, 506
Indinavir, efficacy of in advanced HIV patients, 19
Indonesia, simian T-lymphotropic virus type I infection among wild macaques in, 542
Infant
feeding and mother-to-child transmission, 189
safety and immunogenicity of HIV recombinant envelope vaccines in, 451
Infectivity, time variation in, 527
Injection drug users
geographical differences among HIV-seropositive gay men, 266
HIV prevalence among (letter), 200
HIV-1 subtypes B and E in, 289
in HIV vaccine trials, 519
HTLV-I infection in males versus females, 426
temporal trends in HIV risk behaviors of, 274
Insomnia, in outpatients with HIV infection, 260
Integrase sequences, analysis of, 99
Interleukin-10, enhancing TNF-α activation of HIV-1 transcription, 321
Interleukin-2 receptor, absence of, 332

Japan, hepatitis C virus and HTLV-I coinfection in, 421
Job Corps entrants, HIV prevalence in, 67

Latin America
discontinuous introduction of HIV subtypes B and F into (letter), 310
HTLV-I-associated myelopathy/tropical spastic paraparesis in, 536
HTLV-I/II antibodies among Indian groups from (letter), 548
infant feeding and risk of mother-to-child transmission in, 189
Length of stay, nosocomial bloodstream infections and, 490
Letters to editor
body shape changes in HIV-infected patients, 307
combination antiretroviral therapy including protease inhibitor eliminated transfusion requirements of HIV-infected individuals with anemia of chronic disease, 306
cotton-wool spots in primary HIV infection, 197
*CXCR4* polymorphisms and HIV-1 pathogenesis, 430
effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men, 546
effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men: authors' reply, 547
HIV-2, HTLV-I, and HTLV-II in a semiurban population in East Gabon, 430
HIV prevalence among injection drug users in three northern California communities, 200
HTLV-I/II antibodies among three different Indian groups from Paraguay, 548
introduction of HIV-1 subtype A in French West Indies, 308
molecular and epidemiologic evidence of discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil, 310
rapid progression of HIV infection in HBeAg-positive patients, 198
selecting the optimum dose for new soft gelatin capsule formulation of saquinavir, 195
Liver function tests, hepatitis G virus RNA and, 408
Long terminal repeat transcription, synergistically induced, 321
Long-term nonprogressors, HIV-1 integrase sequences in, 99
Lymphocyte count
in AIDS survival analysis, 403
correlation with CD4+ count and CD4+ percentage, 238
Lymphoid tissue, CD8+ T cell activation and proliferation in, 332
Lysis, CD4 T-cell, 111

*Macaca nemestrina*, simian T-lymphotropic virus type I infection among, 542
Macrolides, for toxoplasmic encephalitis, 50
Macrophage inflammatory protein-1á, increased intracellular levels and advanced HIV, 1
Macrophage-tropic HIV isolates, PBMC susceptibility in, 145
Malabsorption, weight loss and, 34
Medications, factors in recognition and use of, 350
Metabolism
glycosphingolipid, HIV-1-induced perturbations of, 221
in HIV-infected children, 150
Mexiletine, for HIV patients with painful peripheral neuropathy, 367
Military personnel, surveillance of HIV-1 prevalence and subtype in, 165
Minorities, provider attitudes toward participation of in AIDS clinical trials, 245
Modulation, of anti-HIV protease inhibitors, 203
Molecular epidemiology
of discontinuous introduction of HIV subtypes B and F into Brazil (letter), 310
of HIV-1 subtypes B and E in injection drug users, 289
of HIV-1 subtypes in Taiwan, 393

Monocytes, HIV-1 transcription activation in, 321
Mortality, attributable to nosocomial bloodstream infections, 490
Mother-to-infant transmission
  infant feeding and risk of, 189
  maternal and perinatal factors in, 462
Multidrug transporters, interaction with anti-HIV protease inhibitors, 203
Mycobacteremia, in febrile adults, 484
*Mycobacterium avium* complex
  in febrile adults, 484
  prophylaxis for, 387
*Mycobacterium simiae*, in febrile adults, 484
Myelopathy, HTLV-I-associated, 536

**N**-acetylcysteine, for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions, 498
Natural history, of HIV disease and tuberculosis, 361
Nelfinavir, interaction with P-glycoprotein, 203
Neutralizing antibodies, in protection from SIV infection, 441
Nevirapine, survival benefits of, 339
Newborns, assessment for HIV infection in Europe, 296
Nonnucleoside reverse transcriptase inhibitors, phase I study of, 135
Nosocomial bloodstream infections, in HIV-infected patients, 490
Nucleoside reverse transcriptase inhibitors, peak viral load drop in response to, 55
Nutrition, in HIV-infected children, 150

**O**pportunistic infection
  in ambulatory HIV-infected patients, 182
  prophylaxis for in HIV-infected patients receiving medical care, 387
  protease inhibitors for, 130
Oropharyngeal candidiasis, Th1/Th2 cytokines in, 373
Outcome improvement, for cytomegalovirus retinitis, 130
Outpatient population, insomnia in, 260
Outreach programs, HIV seropositivity rates in, 282

**p**24 antigen, body mass index and in asymptomatic HIV-1-infected gay men, 254
Pain, with peripheral neuropathy, 367
Paraguay, HTLV-I/II antibodies among Indian groups from (letter), 548
Partner studies, time variation in HIV infectivity in, 527
Peak reduction, in response to nucleoside reverse transcriptase inhibitors, 55
Pediatrics, safety and immunogenicity of HIV recombinant envelope vaccines in, 451
Peripheral blood mononuclear cells, decreased susceptibility of in heterozygotes for mutant *CCR5* allele, 145
Peripheral neuropathy, mexiletine for, 367
P-glycoprotein, interaction with anti-HIV protease inhibitors, 203
Pharmacokinetics, of zidovudine during pregnancy, 433
Phase I clinical trial, of atevirdine mesylate monotherapy, 135
Phenotypic resistance, efficacy of indinavir in, 19
Placental transfer, of zidovudine, 433
Pneumococcal capsular polysaccharides, time course of antibody response to, 471
*Pneumocystis carinii* pneumonia
  in ambulatory HIV-infected patients, 182
  hypersensitivity reactions to trimethoprim-sulfamethoxazole for, 498
  prophylaxis for, 350, 387
Polymerase chain reaction, for simian T-lymphotropic virus type I infection among wild macaques, 542
Polymorphisms, HIV-1 pathogenesis and (letter), 430
Predictive factors, in peak viral load drop with nucleoside reverse transcriptase inhibitors, 55
Pregnancy
  HIV prevalence during, 296
  zidovudine kinetics during, 433
Prevalence
  among injection drug users (letter), 200
  among young homosexual men, 178
  of HIV-1 in young Thai men, 165
  of HIV-1 subtypes B and E in injection drug users, 289
  in pregnant women in Europe, 296
  trends among childbearing women, 158
Prevention, antiretroviral therapy and viral load effect on attitudes toward, 124
Prognostic indicator/marker
  in HIV-infected children, 230
  nosocomial bloodstream infections as, 490
Program evaluation, for HIV seropositivity rates, 282
Prophylaxis
  failure of in ambulatory HIV-infected patients, 182
  for opportunistic infections in HIV-infected patients, 387
  for *Pneumocystis carinii* pneumonia, 350
Protease inhibitors
  in combination therapy for HIV-infected chronic anemia patients (letter), 306
  efficacy of indinavir with, 19
  factors in recognition and use of, 350
  improved outcome of cytomegalovirus retinitis after, 130
  interaction with P-glycoprotein in human cultured cells, 203
Provider attitudes, toward women and minorities in AIDS clinical trials, 245
Purified protein derivative reactivity, suppression of by hepatitis C virus, 421
Pyrimethamine, for toxoplasmic encephalitis, 50

**R**ace
  HIV prevalence and, 67
  and participation in AIDS clinical trials, 245
  sociodemographic and behavioral characteristics and, 413
Rectal infection, in pathogenic SHIV infection, 6
Regional variation, in substance use among HIV-seropositive gay men, 266
Resting energy expenditure, in children with HIV, 150
Restriction fragment length polymorphism, for HIV-1 C2-V3 region, 74
Reverse transcriptase inhibitor therapy, survival benefits of, 339
Reverse transcriptase mutations, in children treated with zidovudine, 230

Reverse transcriptase nucleoside analogues, efficacy of indinavir added to, 19
Risk behavior
among young homosexual men, 178
antiretroviral therapy and viral load effect on, 124
for cryptosporidiosis in HIV-infected patients, 44
determinants of among young HIV-negative gay and bisexual men, 61
in injection drug users and crack smokers, 274
Risk factors
for HIV and AIDS in African-American women, 413
nosocomial bloodstream infections as, 490
in STD clinic patients, 506
Ritonavir, interaction with P-glycoprotein, 203
Ruptured membrane, duration of in mother-infant transmission, 462
Rural population, sexual behavior among, 80

Saliva, Th1/Th2 cytokines in, 373
Salmonella, in febrile adults, 484
San Francisco, high prevalence of HIV and risk behaviors among gay men of, 178
Saquinavir
interaction with P-glycoprotein, 203
soft gelatin capsule formulation of (letter), 195
SDF1, effects of in AIDS progression, 381
Seroprevalence, of HTLV-I/II among HIV-infected women and women at risk for HIV, 513
Serosurvey, of HIV among childbearing women, 158
Sexual abuse, sexual risk-taking and among gay men, 61
Sexual practices, antiretroviral therapy and viral load effect on, 124
Sexual risk behavior
among rural Chinese, 80
among young homosexual men, 178
for cryptosporidiosis in HIV-infected patients, 44
determinants of among young HIV-negative gay and bisexual men, 61
in injection drug users and crack smokers, 274
Sexually transmitted disease clinics, HIV seroincidence and risk factors in patients of, 506
Simian immunodeficiency virus (SIV)
antibodies and immune reactivity to gp41 in protection against, 441
inhibited replication of, 210
Simian T-lymphotropic virus type I infection, among wild macaques, 542
Simian-human immunodeficiency virus (SHIV), pathogenic, antiviral antibody response to, 6
SIV*mac32H*, in protection from SIV infection, 441
Skin reactivity, to purified protein derivative, suppression of by hepatitis C virus, 421
Snowball sampling, of HTLV-I infected injection drug users, 426
Social harm, to vaccine trial participants, 519
Social support, sexual risk-taking and among gay men, 61
Sociodemographic characteristics, of African-American women with HIV and AIDS, 413
Socioeconomic status, HIV prevalence and, 67
South Africa, total lymphocyte count, CD4+ count, and CD4+ percentage in HIV-1-infected patients of, 238
Substance use/abuse
geographical differences in among HIV-seropositive gay men, 266
temporal trends in HIV risk behaviors with, 274
Sulfonamides, for toxoplasmic encephalitis, 50
Suppressive antiretroviral therapy, HIV-1 DNA decay in, 478
Surveillance
of HIV-1 prevalence and subtype in young Thai men, 165
of HIV prevalence in pregnant women, 296
Survival
anemia and, 29
gender in, 403
reverse transcriptase inhibitor therapies in, 339
tuberculosis and, 361

T cells
latently infected, HIV-1 transcription activation in, 321
SIV replication in, 210
Taiwan, molecular epidemiology and trends of HIV-1 subtypes in, 393
*tax* gene, in simian T-lymphotropic virus type I infection, 542
Temporal trends, in HIV risk behaviors in injection drug users and crack smokers, 274
Testing services, HIV seropositivity rates in, 282
Tetanus toxoid, time course of antibody response to, 471
Thailand
characterizing sera from subjects infects with HIV-1 subtypes B and E in, 315
HIV-1 subtypes B and E in injection drug users of, 289
surveillance of HIV-1 prevalence and subtype in young men of, 165
Th1/Th2 cytokines, in saliva, 373
Total lymphocyte count, correlation with CD4+ count and CD4+ percentage, 238
Toxoplasmic encephalitis, acute therapy for, 50
Toxoplasmosis, prophylaxis for, 387
Transfusions, eliminating requirement for in HIV patients with anemia (letter), 306
Trimethoprim-sulfamethoxazole
hypersensitivity reactions to, 498
for opportunistic infections in HIV-infected patients, 387
Tropical spastic paraparesis, in Brazil, 536
Tuberculosis
in febrile adults, 484
prospective study of HIV disease progression and, 361
Tumor necrosis factor-α, activating HIV-1 transcription, 321

U-87201E, phase I study of, 135
Uganda, community-acquired bloodstream infections among febrile adults in, 484
United States
HIV prevalence trends among childbearing women in, 158
HIV seroincidence and risk factors in STD clinic patients in, 506

Vaccine
challenge stock, for pathogenic SHIV infection, 6

safety and immunogenicity of in HIV-infected infants and children, 451
for SIV infection, 441
trials of, preventing discrimination against volunteers in, 519
Vaginal infection, in pathogenic SHIV infection, 6
Vertical transmission
infant feeding and risk of, 189
maternal and perinatal factors in, 462
Viral hepatitis, in HIV-infected patient sera, 40
Viral load
macrophage inflammatory protein-1á and, 1
in perceived risk of HIV transmission and need for safe sex, 124
response of to nucleoside reverse transcriptase inhibitors, 55

Water-associated risk behaviors, for cryptosporidiosis in HIV-infected patients, 44
Weight, in asymptomatic HIV-1-infected gay men, 254
Weight loss
in asymptomatic HIV-1-infected gay men, 254
in HIV and chronic diarrhea, 34
Women
childbearing, HIV prevalence trends among, 158
HIV prevalence in during pregnancy, 296
HTLV-I/II seroprevalence among, 513
provider attitudes toward participation of in AIDS clinical trials, 245
sociodemographic and behavioral characteristics of, 413

Yeast colonization, oral, 373

Zalcitabine, survival benefits of, 339
Zidovudine
HIV-1 reverse transcriptase gene mutations related to, 230
kinetics of in pregnant baboon following oral administration, 433
survival benefits of, 339